Spectral Diagnostics Announces Board Changes

TORONTO, July 26, 2013 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation") today announced that Mr. Ian Lennox and Mr. Ed McCormack have resigned as directors of the Corporation, effective August 1, 2013.

"Ian as Chairman of the Board of Directors, and Ed as Chairman of the Finance and Audit Committee, have made significant contributions to Spectral. They helped lead our transformation towards a therapeutic focus and lead the process of funding our mission, and achieving IFRS compliance. I am personally very grateful for their insights, leadership and guidance over their many years as board members," said Dr. Paul Walker, President and CEO of Spectral.

Anthony Bihl, Chairman of the Board of Directors added, "Ian and Ed brought exceptional experience, insight, and value to the Spectral Board, as they consistently focused on driving long term shareholder value.  Their contribution will be missed, and I thank them for all they have done for Spectral."

The Nomination & Governance Committee will commence a board governance review process to identify new directors for the board as well as the composition of the committees of the board.

About Spectral Diagnostics

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product (Toraymyxin) for the treatment of septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTC QX under the symbol DIAGF. For more information please visit www.spectraldx.com

SOURCE: Spectral Diagnostics Inc.

Spectral Diagnostics Inc. 

Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext. 2200

Adam Peeler
Investor Relations
416-815-0700 ext. 225
[email protected]